Back HIV Treatment Approved HIV Drugs

Approved HIV Drugs

Genvoya TAF Regimen Works Well with Improved Bone and Kidney Safety at 96 Weeks

The Genvoya single-tablet regimen containing tenofovir alafenamide (TAF) suppressed HIV as well as a similar coformulation containing the older tenofovir disoproxil fumarate (TDF), but demonstrated better bone and kidney tolerability after 2 years of treatment, according to a report in the May 1 edition of the Journal of Acquired Immune Deficiency Syndromes.

alt

Read more:

Tenofovir Resistance May Develop in More than Half of Patients Failing Treatment

More than half of people who experienced failure of a tenofovir-based antiretroviral regimen in sub-Saharan Africa had resistance to tenofovir, a meta-analysis of drug resistance studies published in the January 28 online edition of Lancet Infectious Diseases has shown. The study found that the prevalence of tenofovir resistance after first-line treatment failure ranged from 20% in Western Europe and North America to 56%-60% in sub-Saharan Africa.

alt

Read more:

EACS 2015: Dual Therapy with Protease Inhibitors and Lamivudine Suppresses HIV

Dual antiretroviral regimens consisting of only a boosted HIV protease inhibitor (lopinavir/ritonavir or atazanavir) and a single inexpensive and well-tolerated NRTI may be enough to achieve and maintain HIV suppression in a most patients starting antiretroviral therapy (ART) for the first time or switching from a standard triple regimen, according to a pair of studies presented at the EACS 15th European AIDS Conference last month in Barcelona.

alt

Read more:

6. New TAF Version of Tenofovir Approved in Combo Pill

In November the U.S. Food and Drug Administration announced the approval of Gilead Sciences' Genvoya, a new single-tablet regimen containing the integrase inhibitor elvitegravir, the booster cobicistat, emtricitabine, and tenofovir alafenamide or TAF -- a new formulation that is easier on the kidneys and bones than the older tenofovir disoproxil fumarate (TDF).

alt

Read more:

EACS 2015: Can Dolutegravir Dual Therapy or Monotherapy Keep HIV Suppressed?

The potent integrase inhibitor dolutegravir taken with a single well-tolerated NRTI was able to fully suppress viral load in people initiating antiretroviral treatment for the first time, while dolutegravir alone was able to keep HIV suppressed in most treatment-experienced people who started with undetectable viral load, according to a set of studies presented at the 15th European AIDS Conference this week in Barcelona. After these presentations experts offered evidence in favor of and opposed to simplifying treatment by reducing drug burden, disagreeing about whether this strategy is beneficial or too risky.

alt

Read more: